Recipharm completes Korean serialisation project for Abbott

The Korean project, which began in April 2014, required the Sweden-based CDMO (contract development and manufacturing organization) Recipharm to produce a data matrix code, including serial number, to comply with the regulations that are expected to be similar to what’s foreseen in serialisation in the EU.  

Recipharm applied its solution, designed to achieve full compliance with country-specific regulations, to a blister packaging line. Validation batches are now manufactured released and planned to be shipped to Korea beginning in mid-March. Though similar to the EU, the company said the Korean serialisation differed markedly from what’s expected in China.

From the outset, integration formed a key tenet in the collaboration between the two companies, with the establishment of joint company strategic teams and the sharing of critical information, Recipharm said.   

A company spokesman also told us: "Except from the projects for China and Korea, Recipharm is working on a Group wide project to be able to meet the EU rules.

Stephane Guisado, General Manager at Recipharm in Fontaine added: “Once again, our serialisation platform solution has proved the extent of its adaptability and resourcefulness for differing geographic and multi-country regulatory requirements. Indeed, in this case, it ensured that our customer complied in full with the relevant serialisation regulations set down by Korea.”